Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Jun. 10, 2026	Update on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemia	R&D
Jun. 02, 2026	Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026（PDF/473KB）	R&D
Jun. 01, 2026	Sumitomo Pharma Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change	Corporate
May 29, 2026	Posted Notice of Convocation of the 206th Annual Shareholders' Meeting	Corporate
May 22, 2026	Notice Regarding Results of Capital Increase by way of Third-Party Allotment (Not Implemented)	Finances
May 15, 2026	Posted Conference on FY2025 Financial Results [Webcast]	Finances

Jul. 31, 2026	1st Quarter of FY2026 financial results announcement (scheduled to be disclosed at 3:30 p.m.)
Jun. 25, 2026	206th Annual Shareholders’ Meeting